MDLN

Medline is a scaled, durable healthcare-supply business compounding the top line at a healthy clip: revenue rose to $28.4B in FY2025 (+11.5% YoY), extending a clean three-year ramp from $23.2B (FY2023) to $25.5B (FY2024) to $28.4B. Demand for surgical and medical consumables is recurring and non-discretionary, and the post-IPO balance sheet is visibly healing — long-term debt fell 24% to $12.5B while cash jumped to $1.94B (+874%), and current assets ($10.7B) now cover current liabilities ($2.49B) more than 4x. Operating cash flow of $1.74B and ROE of 10.8% confirm this is a real, profitable enterprise, not a story stock.

The problem is quality of growth and who actually owns the earnings. Gross profit grew only +7.8% and operating income just +3.1% against +11.5% revenue growth — i.e. margins are compressing as the company scales: gross margin is a distribution-thin 26.4%, operating margin 7.8%, net margin 4.1%. More striking, FY2025 diluted EPS is -$0.01 despite $1.16B of net income, a tell of the Up-C / pre-IPO structure where economics accrue to non-public holders. Retained earnings sit at -$7M, so there is no accumulated cushion. The headline P/E of -3594x is meaningless, and with no share count or peer multiple in the data I cannot anchor a defensible price target.